MEDICAL SYSTEM NETWORK Co., Ltd.

Second Quarter (Interim) of Fiscal Year Ending March 2026 Standard Market of Tokyo Stock Exchange; Securities Code: 4350

Data Book

(November 7, 2025)



Table of Contents

 Consolidated Statement of Income and Comprehensive Income Consolidated Statement of Income Consolidated Statement of Comprehensive Income 	• • • 1
2 . Consolidated Balance Sheet	• • • 3
3. Consolidated Statement of Cash Flows	4
4. Key Financial Indicators (consolidated)	• • • 5
5. Dividends	• • • 5
6 . No.of Employees (consolidated)	• • • 5
7. Community Pharmacy Network Segment(1) Community Pharmacy Business(2) Pharmaceutical Network Business	6
8 . Consolidated Earnings Forecast	8

■ About contents covered

- * The contents of this report pertaining future earnings described are based on information the company has held, and on certain assumptions supervising rational judgement, and are not what the company promises to achieve. There are numerous factors that may cause actual earnings to differ.
- * Caution is given to the accuracy of information, and we do not take responsibility for loss etc., as a result of misinformed information.
- * Furthermore, this report is not prepared for the purposes of investment solicitation. Readers are responsible for their own judgement in any decision regarding investments.

1. Consolidated Statement of Income and Comprehensive Income

(1) Consolidated Statement of Income

	E)/0/0004	E)/0/	10005	E\/0/	(ITIIIIOIT YEIT)
	FY3/2024		2025		2026
	Interim		erim	Inte	
	4/2023 - 9/2023	4/2024	- 9/2024	4/2025 -	
			Change		Change
Net sales	56,461	59,761	3,300	63,863	4,102
(YoY)	5.9%	5.8%	_	6.9%	_
Community Pharmacy Network Segment	53,765	57,074	3,308	61,407	4,333
Leasing and Facility related Segment	1,687	1,729	42	1,457	(272)
Meal Catering Segment	1,189	1,177	(12)	1,161	(16)
Home Visit Nursing Segment	155	174	18	169	(4)
Adjustments	(336)	(394)	(57)	(331)	62
Cost of sales	33,008	35,097	2,089	37,617	2,520
(% of Net sales)	58.5%	58.7%	_	58.9%	_
Gross profit	23,453	24,664	1,211	26,246	1,581
(YoY)	5.1%	5.2%	-,	6.4%	- 1,001
(% of Net sales)	41.5%	41.3%	_	41.1%	_
SG&A expenses	21,740	23,636	1,896	24,959	1,323
(% of Net sales)	38.5%	39.6%	1,090	39.1%	1,323
			996		922
Labor costs	12,520	13,406	886	14,240	833
Depreciation	633	754	120	865	111
Amortization of goodwill	561	588	26	541	46
EBITDA	3,247	2,697	(549)	2,993	295
Operating profit	1,712	1,027	(684)	1,286	258
(YoY)	55.7%	(40.0%)	_	25.1%	_
(% of Net sales)	3.0%	1.7%	_	2.0%	_
Community Pharmacy Network Segment	2,947	2,241	(706)	2,557	315
Leasing and Facility related Segment	69	99	29	41	(57)
Meal Catering Segment	(23)	(7)	15	(8)	(1)
Home Visit Nursing Segment	(20)	(12)	8	(10)	1
Adjustments	(1,261)	(1,293)	(32)	(1,292)	0
Non-operating profit	179	180	0	196	16
Interest income and Dividend income	3	3	0	8	4
Other	176	176	0	188	11
Non-operating expenses	199	187	(11)	267	79
Interest expenses	157	130	(26) \(\triangle \)	148	17
Other	42	57	△ 14	119	61
Ordinary profit	1,692	1,020	672	1,215	195
(YoY)	36.2%	(39.7%)	-	19.1%	-
(% of Net sales)	3.0%	1.7%	_	1.9%	_
Extraordinary income	22	56	33	1.970	(41)
Extraordinary Income Extraordinary losses	9	239	229	164	(74)
-	_	837			
Profit before income taxes	1,705		(868)	1,066	228
Income taxes	839	615	(223)	593	(22)
Profit attributable to non-controlling interests	5	14	9	19	5
Profit attributable to owners of parent	861	207	(654)	452	245
(YoY)	71.5%	(76.0%)	_	118.6%	_
(% of Net sales)	1.5%	0.3%	_	0.7%	_

(2) Consolidated Statement of Comprehensive Income

	FY3/2024	FY3/	2025	FY3/	2026
	Interim	Inte	Interim		erim
	4/2023 - 9/2023	4/2024 -	- 9/2024	4/2025	- 9/2025
			Change		Change
Profit	866	221	(645)	472	251
Other comprehensive income	25	11	(14)	(11)	(23)
Valuation difference on available-for-sale securities	12	(2)	(15)	(12)	(9)
Deferred gains or losses on hedges	0	0	0	(2)	(2)
Remeasurements of defined benefit plans, net of tax	12	13	0	2	(10)
Comprehensive income	892	232	(659)	460	228
(YoY)	70.3%	(73.9%)	_	98.1%	_
Comprehensive income attributable to owners of parent	887	218	(668)	440	222
Comprehensive income attributable to non-controlling interests	5	14	9	19	5

2. Consolidated Balance Sheet

	FY3/2025	EV3/	2025	FY3/2026			
	Interim				Interim		
	End of 9/2024	End of	End of 3/2025		9/2025		
	End of 9/2024		Change	Elid Oi	Change		
Total current assets	22,173	22,627	453	22,494			
Cash and deposits	8,689	8,461	(228)	6,464	` '		
Accounts receivable - trade	4,329	5,053	723		` ' '		
Inventories	6,434	6,237	(196)	7,295			
Other	2,719	2,875	155	2,654	(220)		
Total non-current assets	47,803	47,959	156		` ,		
	28,987	28,473	(513)				
Property, plant and equipment Buildings and structures, net	13,428	12,705	(723)	12,543			
Land					` ′		
Leased assets	9,293	9,378	84	9,732			
	4,098	4,503	404	4,423	` '		
Construction in progress	366	89	(276)	268			
Other	1,798	1,796	(2)	1,879			
Intangible assets Goodwill	10,726	9,908	(817)	10,017			
Other	9,944	9,063	(881)	9,116			
	781	845	63	900			
Investment and other assets	8,090	9,578	1,487	9,749			
Investment securities	180	702	522	634	` '		
Guarantee deposits	3,786	4,456	669	4,578			
Deferred tax assets	3,266	3,432	166	•			
Other	856	985	129	934	(50)		
Total assets	69,976	70,586	610	•			
Total current liabilities	28,048	24,377	(3,671)	26,769			
Accounts payable - trade	10,800	11,480	680	11,665			
Short-term borrowings	5,339	588	(4,751)	3,788			
Current portion of long-term Lease obligations	4,567	5,596	1,029	5,408	(188)		
	418	453	34	461	(270)		
Income taxes payable Other	533	864	331	585	` '		
	6,389	5,393	(995)	4,862	` ′		
Total non-current liabilities Long-term borrowings	26,659	29,863	3,204				
Lease obligations	15,188	18,085	2,897	· · · · · · · · · · · · · · · · · · ·	` `		
Provision for retirement benefits for	4,646	5,067	420	4,978	(88)		
directors (and other officers)	690	557	(133)	534	(23)		
Retirement benefit liability	4,709	4,666	(43)	4,876	210		
Other	1,424	1,487	63		34		
Total liabilities	54,708	54,241	(466)	54,480			
Shareholders' equity	15,307	16,184	876				
Share capital	2,128	2,128	-	2,128			
Capital surplus	946	946		946			
Retained earnings	13,124	14,001	876				
Treasury shares	+		010				
-	(891)	(891)		(891)	(0)		
Accumulated other comprehensive income	(101)	75	177	63	(11)		
Non-controlling interests	62	85	23	105	19		
Total net assets	15,268	16,345	1,077				

3. Consolidated Statement of Cash Flows

			(million yen)
	FY3/2024	FY3/2025	FY3/2026
	Interim	Interim	Interim
	4/2023 - 9/2023	4/2024 - 9/2024	4/2025 - 9/2025
Cash flows from operating activities	3,611	517	259
Profit before income taxes	1,705	837	1,066
Depreciation	972	1,081	1,165
Impairment loss	5	223	142
Amortization of goodwill	561	588	541
Increase (decrease) in provision	261	180	(27)
Loss(gain)on disposal of assets and valuation of securities	(21)	(39)	36
Interest and dividend income, Interest expenses	131	127	140
Decrease (increase) in notes and accounts receivable - trade	(239)	(53)	(858)
Decrease (increase) in inventories	(470)	(904)	(988)
Increase (decrease) in notes and accounts payable - trade	198	(167)	(58)
Other	1,279	(211)	49
Subtotal	4,385	1,661	1,208
Interest and dividend income received, interest expenses paid	(130)	(130)	(142)
Income taxes paid	(644)	(1,014)	(806)
Cash flows from investing activities	(1,209)	(785)	(2,486)
Purchase of tangible fixed assets	(968)	(1,456)	(1,397)
Proceeds from sales of tangible fixed assets	0	9	120
Purchase of intangible fixed assets	(122)	(205)	(175)
Proceeds from sales of investment securities	_	_	7
Purchase of shares of subsidiaries resulting in change in scope of consolidation	-	(14)	(139)
Payments for acquisition of businesses	_	_	(568)
Proceeds from sale of businesses	31	1,547	13
Payments of loans receivable	(1)	(170)	(335)
Collection of loans receivable	1	0	201
Payments for guarantee deposits	(132)	(442)	(427)
Proceeds from collection of guarantee deposits	35	56	297
Other	(54)	(110)	(82)
Cash flows from financing activities	(2,899)	685	260
Net increase (decrease) in short-term loans payable	120	4,751	3,200
Proceeds from long-term borrowings	_		300
Repayments of long-term borrowings	(2,630)	(3,676)	(2,824)
Repayments of lease obligations	(205)	(211)	(237)
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation	_	_	(0)
Proceeds from share issuance to non-controlling shareholders	(182)	(177)	(178)
Net increase (decrease) in cash and cash equivalents	(497)	416	(1,966)
Cash and cash equivalents at beginning of period	8,111	8,242	8,431
Cash and cash equivalents at end of period	7,613	8,659	6,464
1 1, 2, 2, 2	. ,510	5,500	5, 10

4. Key Financial Indicators (consolidated)

	FY3/2025	FY3/2025	FY3/2026
	Interim		Interim
	4/2024 - 9/2024	4/2024 - 3/2025	4/2025 - 9/2025
No.of Shares outstanding (including treasury stocks)	30,642,600	30,642,600	30,642,600
No.of Shares outstanding (excluding treasury stocks)	29,228,545	29,228,545	29,228,497
Stock price as of the end of the period (yen)	433	393	476
Market cap(million yen)	12,655	11,486	13,912
EPS (yen)	7.08	43.20	15.48
BPS (yen)	520.26	556.31	565.27
PER (times)	_	9.1	
PBR (times)	0.8	0.7	0.8
ROE (%)	_	8.0	_
ROA (%)	_	4.6	_
Equity ratio (%)	21.7	23.0	23.2

5. Dividends <plan>

	FY3/2024	FY3/2025	FY3/2026
Annual dividend (yen)	12.00	12.00	12.00
Interim (yen)	6.00	6.00	6.00
Year-end (yen)	6.00	6.00	6.00
Total dividends (million yen)	361	357	357
Payout ratio (%)	19.4	27.8	27.0
Dividend yield (%)	1.8	3.1	_

6. No.of Employees (consolidated)

(persons)

	FY3/2025	FY3/	2025	FY3/2	
	Interim	F	0/0005	Inter	
	End of 9/2024	End of	3/2025	End of 9	
Community Phormacy Naturals Comment	3,959	3,930	Change	4,104	Change 174
Community Pharmacy Network Segment			` '	,	
Full-time employees	3,399	3,366	, ,	3,509	
(Pharmacists)	1,589	1,572	(17)	1,641	69
Temporary employees	560	564	4	595	31
(Pharmacists)	309	312	3	337	25
Leasing and Facility related Segment	138	143	5	148	5
Full-time employees	127	132	5	136	4
Temporary employees	11	11	0	12	1
Meal Catering Segment	396	378	(19)	366	(12)
Full-time employees	171	157	(14)	155	(2)
Temporary employees	225	221	(5)	211	(10)
Home Visit Nursing Segment	58	57	(1)	59	1
Full-time employees	44	43	(1)	44	1
Temporary employees	14	14	0	15	0
Corporate	167	176	9	182	6
Full-time employees	153	162	9	167	5
Temporary employees	14	14	0	15	1
Total	4,718	4,684	(34)	4,858	174
Full-time employees	3,894	3,860	(34)	4,011	151
Temporary employees	824	824	0	847	23

^{*} The number of full-time employees is as of the end of each fiscal year. The number of temporary employees is yearly average number of persons employed based on 8-hour conversion.

7. Community Pharmacy Network Segment

(1) Community Pharmacy Business

①No.of pharmacies

		FY3/2024				FY3/2025			FY3/2026 Interim			
		4/2023	- 3/2024			4/2024	- 3/2025			4/2025	- 9/2025	
	Openings	M & A	Closings Transfers	End of FY	Openings	M & A	Closings Transfers	End of FY	Openings	M & A	Closings Transfers	End of FY
No.of pharmacies	13	18	9	450	21	1	15	457	7	8	3	469
Hokkaido area	3	_	5	120	4	1	3	122	_	5	_	127
Tohoku area	1	7	_	32	3	_	1	34	1	-	_	35
Kanto/Koshinetsu area	5	1	2	105	7	_	3	109	3	2	1	113
Tokai/Hokuriku area	_	_	_	44	_	_	_	44	_	-	_	44
Kinki area	1	_	2	52	4	_	2	54	2	1	1	55
Chugoku/Shikoku area	1	_	_	22	_	_	1	21	_	-	1	20
Kyushu/Okinawa area	2	10	_	75	3	_	5	73	1	1	_	75
Care plan centers	_	_	_	1	_	_		1	_	ı	_	1
Drug/cosmetic stores	1	_	1	9	_		* 1	8	1		_	9

^{*} The cosmetics store Nanohana Ebisubashi closed on December 31,2024.

②Dispensing fee breakdown (No.of prescriptions/Unit price)

Special designation (transference) of the process process.										
	FY3/2024		FY3/2025			FY3/2026				
	Interim		Interim			Interim				
	4/2023 - 9/2023		4/2024 - 9/2024			4/2025 - 9/2025				
			Change	Change(%)		Change	Change(%)			
No.of prescriptions(a)(1,000)	4,777	4,947	169	169 3.6%		56	1.1%			
Unit price(b) (yen)	10,033	10,228	195	1.9%	10,583	355	3.5%			
Drug charge per prescription	7,687	7,828	140	1.8%	8,080	253	3.2%			
Technical fee per prescription	2,346	2,400	54	2.3%	2,503	103	4.3%			
Dispensing fee(a)×(b)(million yen)	47,935	50,600	2,664	5.6%	52,957	2,357	4.7%			

③Dispensing fee breakdown by new openings and M&A period

(million yen)

® bisperising fee breat	down by new openings and			(IIIIIIOII yell)		
		FY3/	2025		FY3/2026	
		Inte	erim		Interim	
		4/2024	- 9/2024		4/2025 - 9/2025	
			% of Net sales		% of Net sales	Change
Dispensing fee		50,600	100.0%	52,957	100.0%	2,357
Existing pharmacies	(Openings~3/2024)	49,361	97.6%	50,605	95.6%	1,243
New openings	(4/2024~3/2025)	500	1.0%	1,814	3.4%	1,314
M&A	(4/2024~3/2025)	62	0.1%	117	0.2%	54
New openings	(4/2025~9/2025)	0	_	268	0.5%	268
M&A	(4/2025~9/2025)	0	_	113	0.2%	113
Closings / Transfers		676	1.3%	38	0.1%	(638)

Monthly dispensing fee (All / Existing) (YoY)

(%)

		-, .					· ,
All pharmacies (YoY)	4/2025	5/2025	6/2025	7/2025	8/2025	9/2025	FY3/2026
							Interim
Dispensing fee	4.5	3.5	5.4	2.7	3.1	9.1	4.7
No.of prescriptions	1.5	(1.0)	2.5	(1.2)	(0.4)	5.8	1.1
Unit price	2.9	4.5	2.8	3.9	3.5	3.1	3.5

Existing pharmacies (YoY)	4/2025	5/2025	6/2025	7/2025	8/2025	9/2025	FY3/2026
							Interim
Dispensing fee	2.2	1.1	3.7	0.5	1.3	6.7	2.5
No.of prescriptions	(0.5)	(3.4)	(0.0)	(3.9)	(3.3)	2.4	(1.5)
Unit price	2.7	4.6	3.7	4.6	4.7	4.3	4.1

^{*} Existing pharmacies definition: Pharmacies that have been continuously open since April 1,2024 for the current FY

(2) Pharmaceutical Network Business

①No.of Network affiliates

	F	FY3/2025 (End of 3/2025)			FY3/2026 (End of 9/2025)			
Attribute	MSNW	General		MSNW	General			
	community	network	Total	community	network	Total		
Area	pharmacies	affiliates		pharmacies	affiliates			
Hokkaido	122	240	362	127	252	379		
Tohoku	34	783	817	35	802	837		
Kanto/Koshinetsu	109	3,380	3,489	113	3,568	3,681		
Tokai/Hokuriku	44	1,744	1,788	44	1,863	1,907		
Kinki	54	1,744	1,798	55	1,785	1,840		
Chugoku/Shikoku	21	1,029	1,050	20	1,083	1,103		
Kyushu/Okinawa	73	1,626	1,699	75	1,689	1,764		
Total	457	10,546	11,003	469	11,042	11,511		

②Pharmaceuticals transactions volume

0			(
	FY3/2024	FY3/2025			FY3/2026		
	Interim	Interim			Interim		
	4/2023 - 9/2023	4/2024 - 9/2024			4/2025 - 9/2025		
			Change	Change(%)		Change	Change(%)
Pharmaceuticals transactions volume	303,527	328,894	25,366	8.4%	363,782	34,887	10.6%

8. Consolidated Earnings Forecast

	FY3/	2025	FY3/2026		
	4/2024 - 3/2025		4/2025~3/2026		
	Results	% of Net sales	Forecast	% of Net sales	(YoY)
Net sales	122,387	100.0%	125,500	100.0%	2.5%
Community Pharmacy Network Segment	116,968	95.6%	120,099	95.7%	2.7%
Leasing and Facility related Segment	3,468	2.8%	3,582	2.9%	3.3%
Meal Catering Segment	2,359	1.9%	2,299	1.8%	(2.5%)
Home Visit Nursing Segment	342	0.3%	343	0.3%	0.3%
Adjustments	(751)	_	(826)	l	I
Gross profit	50,736	41.5%	53,420	42.6%	5.3%
SG&A expenses	47,582	38.9%	50,020	39.9%	5.1%
Labor costs	26,662	21.8%	28,465	22.7%	6.8%
Depreciation	1,651	1.3%	1,914	1.5%	15.9%
Amortization of goodwill	1,133	0.9%	1,003	0.8%	(11.5%)
EBITDA	6,569	5.4%	6,890	5.5%	4.9%
Operating profit	3,154	2.6%	3,400	2.7%	7.8%
Community Pharmacy Network Segment	5,626	* 4.8%	5,973	* 5.0%	6.2%
Leasing and Facility related Segment	190	* 5.5%	227	* 6.3%	19.4%
Meal Catering Segment	10	* 0.5%	7	* 0.3%	(28.5%)
Home Visit Nursing Segment	(29)		(16)	_	
Adjustments	(2,644)		(2,791)		
Ordinary profit	3,162	2.6%	3,200	2.5%	1.2%
Profit attributable to owners of parent	1,262	1.0%	1,300	1.0%	3.0%

^{* %} of Segment sales



【 Contact us 】
MEDICAL SYSTEM NETWORK Co., Ltd.
Corporate Management Division

info@msnw.co.jp

E-mail

MEDICAL SYSTEM NETWORK Co., Ltd.